Logo

    car t

    Explore " car t" with insightful episodes like "Stem Cell Clinical Trials and New Therapies for Patients: Alpha Clinic Director's Panel - Sanford Stem Cell Symposium 2022", "Stem Cell Clinical Trials and New Therapies for Patients: Alpha Clinic Director's Panel - Sanford Stem Cell Symposium 2022", "Pharmacists’ Perspective on Managing Multiple Myeloma: FAQs", "Journal Club: Slaying the Sleeper Cells of Aging" and "PODCAST: What to expect in haematology 2021: An interview with Dr Leanne Berkahn" from podcasts like ""Stem Cell Channel (Audio)", "Stem Cell Channel (Video)", "ProCE: The Pharmacy Practice Podcast", "Bio Eats World" and "the limbic"" and more!

    Episodes (9)

    Stem Cell Clinical Trials and New Therapies for Patients: Alpha Clinic Director's Panel - Sanford Stem Cell Symposium 2022

    Stem Cell Clinical Trials and New Therapies for Patients: Alpha Clinic Director's Panel - Sanford Stem Cell Symposium 2022
    CIRM-funded Alpha Stem Cell Clinics are a network of California medical centers that specialize in delivering stem cell clinical trials to patients. Sandra Dillon shares how their work has impacted treatments for her rare cancer. Maria T. Millan, M.D., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Sheila Chari, Ph.D., Noah Federman, M.D., Catriona Jamieson, M.D., Ph.D., Sean Turbeville, Ph.D., and Leo D. Wang, M.D., Ph.D., discuss current clinical trials and the future of stem cell research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38400]

    Stem Cell Clinical Trials and New Therapies for Patients: Alpha Clinic Director's Panel - Sanford Stem Cell Symposium 2022

    Stem Cell Clinical Trials and New Therapies for Patients: Alpha Clinic Director's Panel - Sanford Stem Cell Symposium 2022
    CIRM-funded Alpha Stem Cell Clinics are a network of California medical centers that specialize in delivering stem cell clinical trials to patients. Sandra Dillon shares how their work has impacted treatments for her rare cancer. Maria T. Millan, M.D., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Sheila Chari, Ph.D., Noah Federman, M.D., Catriona Jamieson, M.D., Ph.D., Sean Turbeville, Ph.D., and Leo D. Wang, M.D., Ph.D., discuss current clinical trials and the future of stem cell research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38400]

    Pharmacists’ Perspective on Managing Multiple Myeloma: FAQs

    Pharmacists’ Perspective on Managing Multiple Myeloma: FAQs

    1:08 - Take-home thoughts for R/R MM 
    3:47 - Summary of BCMA-targeted CAR T-cell therapy; Use of novel agents for R/R MM
    6:47 - Information on melphalan flufenamide; Combination approaches with selinexor in clinical practice
    9:59 - Cost considerations for treatment options in R/R MM
    12:25 - Administration considerations for subcutaneous daratumumab and venetoclax in R/R MM

    Faculty

    Kathryn Maples, PharmD, BCOP
    Clinical Pharmacy Specialist, Multiple Myeloma
    Winship Cancer Institute, Emory Healthcare
    Atlanta, Georgia

    Tim Peterson, PharmD, BCOP
    Clinical Pharmacy Specialist – Multiple Myeloma
    Memorial Sloan Kettering Cancer Center
    New York, New York
     

    Content based on a CE activity supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.

    Link to full activity: 
    https://www.proce.com/RRMM

    Journal Club: Slaying the Sleeper Cells of Aging

    Journal Club: Slaying the Sleeper Cells of Aging

    Today we are revisiting a topic and episode that was originally aired back when Journal Club was part of the a16z podcast. We are covering it again in light of a new research article published in Science, as both this episode and this newer research article are trying to find a way to kill senescent cells.

    The article we discuss in this episode, "Senolytic CAR T cells reverse senescence-associated pathologies" by Amor et al, published in Nature, selectively targets senescent cells with engineered T cells.

    The new article, "Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders" by Johmura et al, published in Science, kills senescent cells by inhibiting an enzyme essential for their metabolism.

    So what are senescent cells, and why is killing them so important? Senescent cells are those in a non-dividing but metabolically active state, and what’s interesting is that they play both protective and pathological roles in the body. When senescent cells accumulate, as often happens during aging, they kick off an inflammatory process that underlies many age-related diseases. Thus the targeted destruction of senescent cells has the potential to treat a wide range of conditions, and possibly to improve longevity.

    Both of the approaches described in these two articles have their pros and cons, and it remains to be seen which will be effective in humans, but together they highlight the interest and importance of senescence-killing, or senolytic, methods for future therapeutics.

     

    On this episode, a16z general partner Jorge Conde (@JorgeCondeBio) and bio deal team partner Andy Tran (@andy23tran) join host Lauren Richardson (@lr_bio) to discuss the results and implications of the article "Senolytic CAR T cells reverse senescence-associated pathologies" by Corina Amor, Judith Feucht, Josef Leibold, Yu-Jui Ho, Changyu Zhu, Direna Alonso-Curbelo, Jorge Mansilla-Soto, Jacob A. Boyer, Xiang Li, Theodoros Giavridis, Amanda Kulick, Shauna Houlihan, Ellinor Peerschke, Scott L. Friedman, Vladimir Ponomarev, Alessandra Piersigilli, Michel Sadelain & Scott W. Lowe, published in Nature.

    The introduction also references the article "Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders" by Yoshikazu Johmura, Takehiro Yamanaka, Satotaka Omori, Teh-Wei Wang, Yuki Sugiura, Masaki Matsumoto, Narumi Suzuki, Soichiro Kumamoto, Kiyoshi Yamaguchi, Seira Hatakeyama, Tomoyo Takami, Rui Yamaguchi, Eigo Shimizu, Kazutaka Ikeda, Nobuyuki Okahashi, Ryuta Mikawa, Makoto Suematsu, Makoto Arita, Masataka Sugimoto, Keiichi I. Nakayama, Yoichi Furukawa, Seiya Imoto, Makoto Nakanishi

    CAR T Therapy Cost Control With Laurence Cooper, M.D., Ph.D.

    CAR T Therapy Cost Control With Laurence Cooper, M.D., Ph.D.

    Controlling the cost of personalized medicine: We go behind the scenes of the effort to build a system that simplifies production and reduces the cost of non-viral T cell therapies with Ziopharm Oncology CEO Laurence Cooper, M.D., Ph.D.

    Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

    New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments

    New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments

    In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.

    Presenters:

    Natalie S. Callander, MD
    Professor of Medicine  
    Director, Myeloma Clinical Program  
    University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin

    Shaji Kumar, MD
    Department of Hematology
    Mayo Clinic
    Rochester, Minnesota

    Content based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.

    Link to full program, including associated downloadable slidesets:

     https://bit.ly/3gT324y

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io